Cytogenetic and Molecular Failure at 12 Months will be the Optimal Time Point for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis in Patients with Chronic Myeloid Leukemia: The Analysis Based on 2013 European LeukemiaNet Recommendation

Jae-Yong Kwak

Cytogenetic and Molecular Failure at 12 Months will be the Optimal Time Point for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis in Patients with Chronic Myeloid Leukemia: The Analysis Based on 2013 European LeukemiaNet Recommendation

Jae-Yong Kwak

Department of Medicine

Research output: Contribution to journal › Journal article › peer-review

Original language	Korean
Journal	CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
State	Published - 2017.06.1

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@article{c39f75c444da4c6a80e197eab342586e,

title = "Cytogenetic and Molecular Failure at 12 Months will be the Optimal Time Point for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis in Patients with Chronic Myeloid Leukemia: The Analysis Based on 2013 European LeukemiaNet Recommendation",

author = "Jae-Yong Kwak",

year = "2017",

month = jun,

day = "1",

language = "Korean",

}

Cytogenetic and Molecular Failure at 12 Months will be the Optimal Time Point for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis in Patients with Chronic Myeloid Leukemia: The Analysis Based on 2013 European LeukemiaNet Recommendation. / Kwak, Jae-Yong.
In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 01.06.2017.

Research output: Contribution to journal › Journal article › peer-review

TY - JOUR

T1 - Cytogenetic and Molecular Failure at 12 Months will be the Optimal Time Point for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis in Patients with Chronic Myeloid Leukemia: The Analysis Based on 2013 European LeukemiaNet Recommendation

AU - Kwak, Jae-Yong

PY - 2017/6/1

Y1 - 2017/6/1

M3 - Journal article

JO - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

JF - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

ER -